Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

RCKT

Rocket Pharmaceuticals Inc

Sep 20 • 04:00PM ET

20.17

Dollar change -1.19
Percentage change -5.57	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM XBI VXF VB IBB IWO VBK SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-2.79	Insider Own	7.87%	Shs Outstand	90.28M	Perf Week	2.65%
Market Cap	1.84B	Forward P/E	-	EPS next Y	-2.56	Insider Trans	-5.36%	Shs Float	83.82M	Perf Month	0.85%
Income	-253.26M	PEG	-	EPS next Q	-0.75	Inst Own	97.89%	Short Float	13.04%	Perf Quarter	-10.28%
Sales	0.00M	P/S	-	EPS this Y	0.58%	Inst Trans	5.51%	Short Ratio	12.52	Perf Half Y	-27.21%
Book/sh	4.23	P/B	4.77	EPS next Y	11.70%	ROA	-55.77%	Short Interest	10.93M	Perf Year	-8.15%
Cash/sh	3.06	P/C	6.58	EPS next 5Y	41.70%	ROE	-64.31%	52W Range	16.55 - 32.53	Perf YTD	-32.70%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-9.09%	ROI	-62.14%	52W High	-37.99%	Beta	1.09
Dividend TTM	-	Quick Ratio	7.79	Sales past 5Y	0.00%	Gross Margin	-	52W Low	21.87%	ATR (14)	1.15
Dividend Ex-Date	-	Current Ratio	7.79	EPS Y/Y TTM	16.29%	Oper. Margin	0.00%	RSI (14)	51.81	Volatility	7.26% 5.51%
Employees	268	Debt/Eq	0.07	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.13	Target Price	47.15
Option/Short	Yes / Yes	LT Debt/Eq	0.06	EPS Q/Q	9.00%	Payout	-	Rel Volume	1.41	Prev Close	21.36
Sales Surprise	-	EPS Surprise	-2.49%	Sales Q/Q	-	Earnings	Aug 05 AMC	Avg Volume	872.67K	Price	20.17
SMA20	4.80%	SMA50	-2.66%	SMA200	-17.46%	Trades		Volume	1,233,760	Change	-5.57%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-02-24	Initiated	Goldman	Neutral	$39
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight	$65
Feb-01-23	Initiated	Morgan Stanley	Overweight	$45
Nov-08-22	Initiated	Canaccord Genuity	Buy	$53
Nov-01-22	Initiated	BTIG Research	Buy	$35
Jul-08-22	Initiated	Raymond James	Outperform	$22
Oct-20-21	Resumed	Cowen	Outperform
Mar-02-21	Initiated	Stifel	Buy	$64
Feb-18-21	Initiated	Needham	Buy	$75
Dec-16-20	Initiated	UBS	Buy	$75
Dec-08-20	Downgrade	Oppenheimer	Outperform → Perform
Jul-02-20	Initiated	JP Morgan	Overweight
Jun-25-20	Resumed	BofA/Merrill	Buy	$34
Jun-01-20	Resumed	Oppenheimer	Outperform
Nov-06-19	Initiated	Chardan Capital Markets	Buy	$30
Sep-26-19	Initiated	Piper Jaffray	Overweight
Apr-23-19	Initiated	Robert W. Baird	Outperform
Mar-15-19	Initiated	BofA/Merrill	Buy	$27
Feb-05-19	Initiated	Oppenheimer	Outperform	$39
Sep-13-18	Initiated	Ladenburg Thalmann	Buy	$30

Show Previous Ratings

Sep-17-24 07:00AM	Rocket Pharmaceuticals Announces Completion of Enrollment in Phase 2 Pivotal Trial of RP-A501 for the Treatment of Danon Disease (Business Wire) +13.54%
Sep-10-24 07:00AM	Rocket Pharmaceuticals Announces Appointment of Mikael Dolsten, M.D., Ph.D., to Board of Directors (Business Wire)
Aug-27-24 07:00AM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-25-24 09:06AM	Morgan Stanley Predicts up to 220% Jump for These 2 Strong Buy Stocks (TipRanks)
Aug-05-24 09:55PM	RCKT Stock Earnings: Rocket Pharmaceuticals Misses EPS for Q2 2024 (InvestorPlace)
04:01PM	Loading…
04:01PM	Rocket Pharmaceuticals Reports Second Quarter 2024 Financial Results and Highlights Recent Progress (Business Wire)
Jun-28-24 12:30PM	FDA Again Delays Approval of Rocket Pharmaceuticals' Gene Therapy Treatment (Investopedia)
07:27AM	Rocket Pharmaceuticals Provides Regulatory Update on KRESLADI (marnetegragene autotemcel; marne-cel) (Business Wire)
Jun-05-24 11:30AM	Why Is Rocket Pharmaceuticals (RCKT) Down 4.8% Since Last Earnings Report? (Zacks)
May-29-24 07:00AM	Rocket Pharmaceuticals Receives Orphan Medicinal Product Designation from the European Commission for RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (Business Wire)
May-10-24 06:00AM	Rocket Pharmaceuticals Presents Positive Data from LV Hematology Portfolio at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) (Business Wire)
May-07-24 11:26AM	Rocket's (RCKT) Q1 Loss Narrower Than Expected, Sales Nil (Zacks)
May-06-24 09:55PM	RCKT Stock Earnings: Rocket Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
04:01PM	Rocket Pharmaceuticals Reports First Quarter 2024 Financial Results and Highlights Recent Progress (Business Wire)
Apr-30-24 12:00PM	Rocket Pharmaceuticals (RCKT) Upgraded to Buy: Here's Why (Zacks)
11:33AM	Loading…
Apr-24-24 11:33AM	Should You Retain Your Conviction in Rocket Pharmaceuticals (RCKT)? (Insider Monkey)
07:39AM	Should You Hold Immunovant (IMVT)? (Insider Monkey)
Apr-03-24 11:32AM	EMA Accepts Rocket (RCKT) Gene Therapy Filing for Fanconi Anemia (Zacks)
Apr-02-24 06:00AM	Rocket Pharmaceuticals Announces European Medicines Agency Acceptance of RP-L102 Marketing Authorization Application for the Treatment of Fanconi Anemia (Business Wire)
Mar-27-24 11:30AM	Why Is Rocket Pharmaceuticals (RCKT) Down 13.6% Since Last Earnings Report? (Zacks)
Mar-26-24 04:01PM	Rocket Pharmaceuticals Announces Appointment of Aaron Ondrey as Chief Financial Officer and Additional Updates to Corporate Leadership Team (Business Wire)
Feb-27-24 12:20PM	Rocket (RCKT) Registers Narrower-Than-Expected Loss in Q4 (Zacks)
Feb-26-24 04:01PM	Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress (Business Wire)
Feb-13-24 07:00AM	Rocket Pharmaceuticals Announces Update on FDA Review Timeline of KRESLADI (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) (Business Wire)
Jan-22-24 03:39AM	Should You Maintain Your Conviction in Rocket Pharmaceuticals (RCKT)? (Insider Monkey) +5.61%
Jan-04-24 11:55AM	Amazon and Nvidia Stock Have a Lot More Growth Ahead, This Manager Says (Barrons.com)
Jan-02-24 04:01PM	Rocket Pharmaceuticals to Present at 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-12-23 07:00AM	Rocket Pharmaceuticals Appoints R. Keith Woods to Board of Directors (Business Wire)
Nov-23-23 12:16PM	Billionaire Lee Ainslies Top 10 Stock Picks (Insider Monkey)
Nov-15-23 11:17AM	Rocket (RCKT) Surges 40% in 3 Months on Regulatory Updates (Zacks)
09:55AM	Loading…
Nov-09-23 09:55AM	Wall Street Analysts See a 167.09% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High? (Zacks) -7.15%
Nov-06-23 04:15PM	Rocket Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance) -5.00%
04:04PM	Rocket Pharmaceuticals Reports Third Quarter 2023 Financial Results and Highlights Recent Progress (Business Wire)
Nov-05-23 07:30AM	With This Rally, Rocket Just Might Take Off (TheStreet.com)
Nov-02-23 06:26PM	Rocket Pharmaceuticals Stock Sees Improved Price Strength (Investor's Business Daily) +9.21%
Oct-27-23 02:49PM	Rocket Pharmaceuticals Stock Sees RS Rating Pops Higher (Investor's Business Daily)
Oct-20-23 03:18AM	Should You Hold Rocket Pharmaceuticals (RCKT)? (Insider Monkey)
Oct-19-23 07:00AM	Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral and AAV Gene Therapies at the 30th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) (Business Wire)
Oct-02-23 07:00AM	Rocket Pharmaceuticals Announces FDA Acceptance of Biologics License Application with Priority Review for RP-L201 (marnetegragene autotemcel) for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I) (Business Wire) -5.08%
Sep-26-23 04:01PM	Rocket Pharmaceuticals to Participate in the Chardan 7th Annual Genetic Medicines Conference (Business Wire)
Sep-23-23 09:45AM	Better Gene Editing Stock: Intellia Therapeutics vs. Rocket Pharmaceuticals (Motley Fool)
Sep-18-23 07:30AM	Rocket Pharmaceuticals Stock Is Blasting Off, but Here's Why You Should Tread Carefully (Motley Fool)
Sep-15-23 11:00AM	Here's Why Rocket Pharmaceuticals (RCKT) Rises 53.8% in a Week (Zacks)
Sep-14-23 10:12AM	Biotech Stock Roundup: MRNAs Pipeline News, RCKT, BCYC Rally on Study Updates (Zacks) +13.28%
Sep-13-23 04:34PM	These Stocks Moved the Most Today: American Airlines, Moderna, Ford, Citigroup, Apple, and More (Barrons.com) +38.85%
01:50PM	Stock Market Not Too Rattled By Inflation Data; Trucking Stock Gets A Bounce (Investor's Business Daily)
01:36PM	These Stocks Are Moving the Most Today: American Airlines, Moderna, Ford, Citigroup, Apple, and More (Barrons.com)
12:30PM	Stock Market Weighs In On Inflation Data; Vaccine Maker Leads The S&P 500 (Investor's Business Daily)
12:23PM	What's Going On With Gene Therapy-Focused Rocket Pharmaceuticals Stock Today? (Benzinga)
12:15PM	Rocket Pharmaceuticals, Moderna rise; American Airlines, Spirit Airlines fall, Wednesday, 9/13/2023 (AP Finance)
11:56AM	Why Shares of Rocket Pharmaceuticals Are Taking Off on Wednesday (Motley Fool)
10:54AM	Rocket Pharmaceuticals Stock Jumps Most Since 2020. New Gene Therapy Is Potential Value Driver. (Barrons.com)
07:24AM	5 Things to Know Before Markets Open (Investopedia)
12:01AM	Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock (Business Wire)
Sep-12-23 04:02PM	Rocket Pharmaceuticals Announces Proposed Public Offering of Common Stock (Business Wire)
04:01PM	Rocket Pharmaceuticals Reaches FDA Alignment on Pivotal Phase 2 Trial Design for RP-A501 in Danon Disease (Business Wire)
Sep-06-23 04:05PM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Aug-10-23 07:14AM	Rocket Pharmaceuticals: Q2 Earnings Snapshot (AP Finance)
07:00AM	Rocket Pharmaceuticals Reports Second Quarter 2023 Financial Results and Highlights Recent Progress (Business Wire)
Jul-29-23 11:39AM	10 Oversold Biotech Stocks to Buy (Insider Monkey)
Jul-28-23 03:57PM	12 Stocks with Biggest Upside Potential According to Analysts (Insider Monkey) +6.25%
Jun-12-23 04:34PM	3 Small-Cap Stocks You Cant Ignore Now (InvestorPlace)
Jun-09-23 09:24AM	Rocket (RCKT) Heart Disease Drug Gets Fast Track & Orphan Drug Tag (Zacks)
Jun-08-23 07:00AM	Rocket Pharmaceuticals Receives FDA Fast Track and Orphan Drug Designations for RP-A601 Gene Therapy for PKP2 Arrhythmogenic Cardiomyopathy (ACM) (Business Wire)
May-31-23 07:00AM	Rocket Pharmaceuticals Receives European Medicines Agency (EMA) Priority Medicines (PRIME) Designation for RP-A501 Gene Therapy for Danon Disease (Business Wire)
May-23-23 07:00AM	Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-L301 Gene Therapy for Pyruvate Kinase Deficiency (PKD) (Business Wire)
May-19-23 06:00AM	Rocket Pharmaceuticals Presents Positive Data from LV Hematology and AAV Cardiovascular Gene Therapy Programs at the 26th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) (Business Wire)
May-18-23 06:12AM	Heres Why Rocket Pharmaceuticals (RCKT) Stock Suffered in Q1 (Insider Monkey)
May-17-23 04:26PM	Fed, labor market concerns showing 'some dents in the armor of the consumer': Strategist (Yahoo Finance Video)
May-09-23 07:00AM	Rocket Pharmaceuticals Announces FDA Clearance of IND for Clinical Trial of RP-A601 for PKP2 Arrhythmogenic Cardiomyopathy (ACM) (Business Wire)
May-04-23 04:21PM	Rocket Pharmaceuticals: Q1 Earnings Snapshot (AP Finance) +5.24% +12.36%
04:01PM	Rocket Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Progress (Business Wire)
May-03-23 04:01PM	Rocket Pharmaceuticals to Participate in the Bank of America Securities 2023 Healthcare Conference (Business Wire)
Apr-11-23 04:01PM	Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences (Business Wire)
Apr-04-23 04:01PM	Rocket Pharmaceuticals Announces Leadership Expansion to Support Company on Evolution Towards Commercial Stage (Business Wire)
Mar-01-23 04:01PM	Rocket Pharmaceuticals to Participate in the 43rd Annual Cowen Health Care Conference (Business Wire) +5.41%
Feb-27-23 04:01PM	Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial and Operational Results (Business Wire)
Feb-09-23 04:01PM	Rocket Pharmaceuticals to Present at the SVB Securities Global Biopharma Conference (Business Wire)
Feb-07-23 07:00AM	Rocket Pharmaceuticals Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for RP-A501 Gene Therapy for Danon Disease (Business Wire)
Feb-05-23 09:07AM	Even with Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) stock down 7.7% this week, insiders who bought recently netted around US$70k (Simply Wall St.)
Jan-28-23 01:30PM	12 Cash-Rich Small Cap Stocks To Invest In (Insider Monkey)
Jan-23-23 10:15AM	Rocket Pharmaceuticals (RCKT) Could Find a Support Soon, Here's Why You Should Buy the Stock Now (Zacks)
09:55AM	Wall Street Analysts Think Rocket Pharmaceuticals (RCKT) Could Surge 163.35%: Read This Before Placing a Bet (Zacks)
Jan-09-23 04:01PM	Rocket Pharmaceuticals Expands Cardiac Gene Therapy Portfolio with Addition of RP-A601 for PKP2-ACM and Announces Positive Updated Phase 1 Data for RP-A501 in Danon Disease (Business Wire)
Jan-06-23 09:55AM	Wall Street Analysts Believe Rocket Pharmaceuticals (RCKT) Could Rally 170.92%: Here's is How to Trade (Zacks)
Jan-03-23 04:01PM	Rocket Pharmaceuticals to Present at 41st Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-22-22 06:00AM	Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting (Business Wire) -13.90%
Dec-12-22 10:00AM	Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Pyruvate Kinase Deficiency and Severe Leukocyte Adhesion Deficiency-I Programs at the 64th American Society of Hematology (ASH) Annual Meeting (Business Wire) +6.58%
Dec-11-22 07:21PM	TipRanks Perfect 10 List: These 3 Top-Rated Stocks Could Shine in 2023 (TipRanks)
Dec-01-22 04:01PM	Rocket Pharmaceuticals Completes Acquisition of Renovacor (Business Wire) +8.10%
Nov-21-22 08:00AM	Rocket Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-16-22 07:59AM	A Look At The Fair Value Of Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) (Simply Wall St.) -5.99%
Nov-03-22 04:01PM	Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress (Business Wire)
09:00AM	Rocket Pharmaceuticals Announces Presentations Highlighting AAV and Lentiviral Gene Therapies at Upcoming Scientific Congresses (Business Wire)
Oct-27-22 09:55AM	Wall Street Analysts See an 184% Upside in Rocket Pharmaceuticals (RCKT): Can the Stock Really Move This High? (Zacks)
Oct-14-22 06:35PM	Alkermes, Allakos, and Other Stocks See Action From Activist Investors (Barrons.com) +7.10%
Oct-12-22 06:00AM	Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT) (Business Wire)
Oct-11-22 09:55AM	Does Rocket Pharmaceuticals (RCKT) Have the Potential to Rally 212% as Wall Street Analysts Expect? (Zacks)
Oct-10-22 08:00AM	Rocket Pharmaceuticals to Present at the 2022 Cell & Gene Meeting on the Mesa (Business Wire)
Oct-03-22 11:21PM	Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock (Business Wire) +11.10%

Rocket Pharmaceuticals, Inc. is a clinical-stage biotechnology company, which engages in the development of gene therapy treatment options for rare and devastating pediatric diseases. Its multi-platform development approach applies the lentiviral vector and adeno-associated viral vector gene therapy platforms. Its clinical program is an LVV-based gene therapy for the treatment of Fanconi Anemia (FA), a difficult to treat genetic disease that leads to bone marrow failure and potentially cancer. The company was founded on July 7, 1999 and is headquartered in Cranbury, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Militello John	See Remarks	Aug 16 '24	Sale	18.50	1,064	19,688	51,451	Aug 20 04:26 PM
Patel Kinnari	See Remarks	Aug 16 '24	Sale	18.50	3,989	73,812	396,983	Aug 20 04:26 PM
Shah Gaurav	CEO	Aug 16 '24	Sale	18.50	9,650	178,564	718,419	Aug 20 04:26 PM
Wilson Martin	General Counsel	Aug 16 '24	Sale	18.50	1,027	19,004	64,735	Aug 20 04:26 PM
Militello John	Officer	Aug 16 '24	Proposed Sale	18.50	1,064	19,688		Aug 16 03:39 PM
Patel Kinnari	Officer	Aug 16 '24	Proposed Sale	18.50	3,989	73,810		Aug 16 03:29 PM
Wilson Martin	Officer	Aug 16 '24	Proposed Sale	18.50	1,027	19,003		Aug 16 03:23 PM
Shah Gaurav	Officer	Aug 16 '24	Proposed Sale	18.50	9,650	178,559		Aug 16 03:16 PM
Militello John	See Remarks	Jul 22 '24	Sale	23.02	812	18,688	52,515	Jul 24 04:05 PM
White Mark Andrew	See Remarks	Jul 08 '24	Sale	20.39	3,026	61,715	72,220	Jul 09 04:05 PM
Militello John	See Remarks	May 16 '24	Sale	23.35	1,079	25,195	53,327	May 20 04:36 PM
Shah Gaurav	CEO	May 14 '24	Option Exercise	0.00	17,662	0	646,134	May 20 04:33 PM
Shah Gaurav	CEO	May 16 '24	Sale	23.35	9,790	228,596	728,069	May 20 04:33 PM
Wilson Martin	General Counsel	May 14 '24	Option Exercise	0.00	2,420	0	21,100	May 20 04:29 PM
Wilson Martin	General Counsel	May 16 '24	Sale	23.35	1,048	24,471	65,762	May 20 04:29 PM
Patel Kinnari	See Remarks	May 14 '24	Option Exercise	0.00	9,543	0	301,824	May 20 04:26 PM
Patel Kinnari	See Remarks	May 16 '24	Sale	23.35	4,046	94,474	400,972	May 20 04:26 PM
Militello John	See Remarks	Apr 22 '24	Sale	22.87	833	19,051	54,406	Apr 24 04:06 PM
SOUTHWELL DAVID P	Director	Apr 12 '24	Option Exercise	4.34	70,000	303,940	165,160	Apr 16 05:45 PM
SOUTHWELL DAVID P	Director	Apr 15 '24	Option Exercise	4.34	29,624	128,627	124,784	Apr 16 05:45 PM
SOUTHWELL DAVID P	Director	Apr 12 '24	Sale	24.36	70,000	1,705,265	95,160	Apr 16 05:45 PM
SOUTHWELL DAVID P	Director	Apr 15 '24	Sale	24.05	10,000	240,520	114,784	Apr 16 05:45 PM
White Mark Andrew	See Remarks	Apr 08 '24	Sale	24.64	12,532	308,763	75,226	Apr 10 08:39 PM
Makker Gotham	Director	Mar 21 '24	Sale	28.43	274,000	7,790,943	365,912	Mar 25 08:58 PM
Militello John	See Remarks	Mar 21 '24	Sale	28.10	2,490	69,979	55,239	Mar 25 08:54 PM
Militello John	See Remarks	Feb 29 '24	Option Exercise	12.55	10,000	125,500	31,517	Mar 04 06:54 PM
Militello John	See Remarks	Feb 29 '24	Sale	29.84	10,000	298,450	21,517	Mar 04 06:54 PM
Wilson Martin	General Counsel	Feb 29 '24	Sale	29.33	4,100	120,257	18,680	Mar 04 06:48 PM
Wilson Martin	General Counsel	Feb 16 '24	Sale	29.84	3,576	106,701	6,136	Feb 21 08:54 PM
Patel Kinnari	See Remarks	Feb 16 '24	Sale	29.84	7,132	212,805	238,346	Feb 21 08:54 PM
Militello John	See Remarks	Feb 16 '24	Sale	29.84	3,238	96,615	13,195	Feb 21 08:54 PM
Shah Gaurav	CEO	Feb 16 '24	Sale	29.84	20,272	604,876	554,762	Feb 21 08:54 PM
Patel Kinnari	See Remarks	Feb 14 '24	Option Exercise	0.00	26,189	0	245,478	Feb 16 04:05 PM
Militello John	See Remarks	Feb 14 '24	Option Exercise	0.00	6,274	0	16,433	Feb 16 04:05 PM
Militello John	See Remarks	Jan 22 '24	Sale	27.20	638	17,356	10,159	Jan 23 04:22 PM
Militello John	See Remarks	Jan 18 '24	Option Exercise	0.00	1,586	0	10,797	Jan 22 04:05 PM
Makker Gotham	Director	Nov 15 '23	Sale	22.53	20,000	450,646	1,296,497	Nov 16 07:24 PM
Patel Kinnari	See Remarks	Nov 14 '23	Option Exercise	0.00	3,989	0	220,437	Nov 16 07:17 PM
Militello John	See Remarks	Nov 14 '23	Option Exercise	0.00	725	0	9,485	Nov 16 06:58 PM
Militello John	See Remarks	Oct 20 '23	Sale	17.06	564	9,623	8,760	Oct 25 09:38 AM
Patel Kinnari	See Remarks	Oct 05 '23	Option Exercise	0.00	3,333	0	101,594	Oct 10 04:11 PM
Makker Gotham	Director	Sep 28 '23	Sale	21.03	10,312	216,880	1,321,174	Oct 02 09:02 PM
Makker Gotham	Director	Sep 29 '23	Sale	21.14	4,677	98,864	1,316,497	Oct 02 09:02 PM

Open in Screener

PTCT

PTC Therapeutics Inc

Sep 20 • 04:00PM ET

36.64

Dollar change +0.48
Percentage change 1.33	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

PTCT PTC Therapeutics Inc daily Stock Chart

Held by: VTI IWM VB VXF XBI VBK IBB IWO SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-6.32	Insider Own	3.29%	Shs Outstand	75.71M	Perf Week	7.80%
Market Cap	2.82B	Forward P/E	-	EPS next Y	-4.15	Insider Trans	-1.11%	Shs Float	74.40M	Perf Month	7.99%
Income	-479.52M	PEG	-	EPS next Q	-1.51	Inst Own	103.39%	Short Float	7.56%	Perf Quarter	0.33%
Sales	900.45M	P/S	3.13	EPS this Y	37.58%	Inst Trans	2.02%	Short Ratio	8.21	Perf Half Y	21.45%
Book/sh	-12.75	P/B	-	EPS next Y	20.59%	ROA	-29.47%	Short Interest	5.63M	Perf Year	43.52%
Cash/sh	14.21	P/C	2.58	EPS next 5Y	-9.51%	ROE	-	52W Range	17.53 - 40.69	Perf YTD	32.95%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-24.94%	ROI	-	52W High	-9.95%	Beta	0.65
Dividend TTM	-	Quick Ratio	2.17	Sales past 5Y	29.08%	Gross Margin	71.23%	52W Low	109.01%	ATR (14)	1.58
Dividend Ex-Date	-	Current Ratio	2.23	EPS Y/Y TTM	25.01%	Oper. Margin	-21.37%	RSI (14)	66.80	Volatility	4.14% 4.45%
Employees	995	Debt/Eq	-	Sales Y/Y TTM	9.98%	Profit Margin	-53.25%	Recom	2.47	Target Price	39.71
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	51.43%	Payout	-	Rel Volume	1.34	Prev Close	36.16
Sales Surprise	1.87%	EPS Surprise	-15.19%	Sales Q/Q	-12.68%	Earnings	Aug 08 AMC	Avg Volume	685.43K	Price	36.64
SMA20	8.34%	SMA50	10.02%	SMA200	19.16%	Trades		Volume	919,978	Change	1.33%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-04-24	Initiated	Robert W. Baird	Outperform	$44
Aug-26-24	Resumed	UBS	Buy	$47
May-20-24	Upgrade	Raymond James	Underperform → Mkt Perform
Dec-19-23	Downgrade	Morgan Stanley	Equal-Weight → Underweight	$28
Dec-08-23	Initiated	Wells Fargo	Overweight	$37
Oct-30-23	Upgrade	Oppenheimer	Perform → Outperform	$165
Oct-27-23	Downgrade	Citigroup	Neutral → Sell	$29 → $17
Oct-06-23	Downgrade	Truist	Buy → Hold	$45 → $25
Sep-18-23	Downgrade	Citigroup	Buy → Neutral	$55 → $28
Sep-15-23	Downgrade	Raymond James	Outperform → Underperform
Mar-17-23	Initiated	SVB Securities	Market Perform	$48
Dec-14-22	Initiated	Goldman	Sell	$35
Sep-12-22	Initiated	Jefferies	Buy	$62
Sep-09-22	Initiated	Morgan Stanley	Equal-Weight	$54
Sep-01-22	Initiated	Citigroup	Buy	$70
Apr-04-22	Resumed	Cantor Fitzgerald	Overweight	$64 → $63
Oct-18-21	Downgrade	BofA Securities	Neutral → Underperform	$38
Apr-26-21	Resumed	Credit Suisse	Neutral	$54
Mar-29-21	Upgrade	RBC Capital Mkts	Underperform → Sector Perform	$47
Feb-12-21	Downgrade	BofA Securities	Buy → Neutral

Show Previous Ratings

Sep-12-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Aug-28-24 04:30PM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Aug-19-24 03:33PM	PTC Therapeutics Stock Earns RS Rating Upgrade To 83 (Investor's Business Daily)
Aug-08-24 05:15PM	PTC Therapeutics (PTCT) Reports Q2 Loss, Misses Revenue Estimates (Zacks)
04:09PM	PTC Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Loading…
04:01PM	PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results (PR Newswire)
Aug-06-24 09:15AM	Unlocking Q2 Potential of PTC Therapeutics (PTCT): Exploring Wall Street Estimates for Key Metrics (Zacks)
Jul-30-24 08:00AM	PTC Therapeutics Announces Sepiapterin NDA Submission to FDA (PR Newswire)
Jul-25-24 04:30PM	PTC Therapeutics to Host Conference Call to Discuss Second Quarter 2024 Financial Results (PR Newswire)
10:02AM	Will PTC Therapeutics (PTCT) Report Negative Q2 Earnings? What You Should Know (Zacks)
Jul-01-24 08:00AM	PTC Therapeutics (PTCT) Down on Negative CHMP Opinion on DMD Drug (Zacks)
Jun-28-24 04:08PM	PTC's Journey Of 'Twist And Doubt' Continues With Another Rejection; Shares Tumble (Investor's Business Daily) -11.77%
08:53AM	PTC Therapeutics Tumbles After European Regulators Reject Its Drug Again (Investor's Business Daily)
07:49AM	PTC faces another Duchenne drug rejection; Coherus sells Humira biosimilar (BioPharma Dive)
06:00AM	CHMP Issues Negative Opinion on Translarna Following European Commission Request for Review (PR Newswire)
04:44AM	Loading…
Jun-24-24 04:44AM	PTC Therapeutics (PTCT) Soars 9.7%: Is Further Upside Left in the Stock? (Zacks)
Jun-21-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +9.70%
Jun-20-24 08:19AM	FDA lifts hold on PTC Huntingtons disease trial (BioPharma Dive) -6.54%
06:30AM	Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients (PR Newswire)
Jun-04-24 06:00AM	The 3 Most Undervalued Biotech Stocks to Buy in June 2024 (InvestorPlace)
May-29-24 08:00AM	PTC Therapeutics to Participate at Upcoming Investor Conference (PR Newswire)
May-28-24 08:30AM	PTC Therapeutics Announces Validation of Sepiapterin European MAA (PR Newswire)
May-25-24 02:41AM	Insider Sale: Director Jerome Zeldis Sells 20,000 Shares of PTC Therapeutics Inc (PTCT) (GuruFocus.com)
May-21-24 12:26PM	PTC Therapeutics (PTCT) Up as EC Returns CHMP Opinion on DMD Drug (Zacks)
10:34AM	Goldman Sachs Adjusts PTC Therapeutics Price Target to $32 From $18, Maintains Sell Rating (MT Newswires)
May-20-24 04:05PM	PTC Therapeutics Stock Soars As Its Biggest Drug 'Lives To Fight Another Day' (Investor's Business Daily) +21.23%
12:36PM	Raymond James Upgrades PTC Therapeutics to Market Perform From Underperform (MT Newswires)
12:20PM	PTC Therapeutics Announces European Commission Returns Translarna Opinion to CHMP For Re-evaluation (PR Newswire)
08:57AM	Sector Update: Health Care (MT Newswires)
08:45AM	PTC Therapeutics Says European Commission Seeking Review of Negative Opinion on Translarna (MT Newswires)
07:45AM	Loading…
07:45AM	European Commission, in unprecedented move, declines to revoke approval of PTC Duchenne drug (BioPharma Dive)
May-14-24 09:10AM	Sector Update: Health Care Stocks Steady Premarket Tuesday (MT Newswires)
08:51AM	Sector Update: Health Care (MT Newswires)
08:26AM	PTC Therapeutics Gets FDA Priority Review for Upstaza Biologics License Application (MT Newswires)
07:30AM	PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza (PR Newswire)
May-02-24 08:00AM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
May-01-24 02:45PM	PTC Therapeutics Stock Sees IBD RS Rating Climb To 72 (Investor's Business Daily) +6.25%
Apr-30-24 12:25PM	PTC Therapeutics, Inc. (NASDAQ:PTCT) Q1 2024 Earnings Call Transcript (Insider Monkey)
Apr-29-24 06:11AM	Morgan Stanley Upgrades PTC Therapeutics to Equalweight From Underweight, Adjusts PT to $30 From $28 (MT Newswires) +12.50%
Apr-26-24 03:57PM	Sector Update: Health Care Stocks Edge Higher Late Afternoon (MT Newswires) +12.08%
11:16AM	PTC Therapeutics Shares Rise After Better-Than-Expected Q1 Results (MT Newswires)
07:11AM	Q1 2024 PTC Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
03:35AM	PTC Therapeutics Inc (PTCT) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth ... (GuruFocus.com)
Apr-25-24 08:56PM	PTCT Stock Earnings: PTC Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:00PM	Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics (Zacks)
05:39PM	PTC Therapeutics Q1 2024 Earnings: A Detailed Financial Review (GuruFocus.com)
04:53PM	PTC Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:05PM	PTC Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results (PR Newswire)
Apr-23-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Apr-18-24 10:01AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Apr-11-24 08:00AM	PTC Therapeutics to Host Conference Call to Discuss First Quarter 2024 Financial Results (PR Newswire)
Mar-28-24 08:30AM	PTC Announces Submission of Sepiapterin MAA for Treatment of PKU to EMA (PR Newswire)
Mar-25-24 10:00AM	A Comprehensive Look at Sarepta's Growth and Innovation (GuruFocus.com)
Mar-20-24 02:00PM	PTC Therapeutics (PTCT) Up on Positive Regulatory Updates (Zacks)
Mar-19-24 07:30AM	PTC Therapeutics Provides Key Regulatory Updates (PR Newswire)
Mar-02-24 08:56AM	PTC Therapeutics, Inc. (NASDAQ:PTCT) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-01-24 06:51AM	Q4 2023 PTC Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) +13.34%
Feb-29-24 06:00PM	Here's What Key Metrics Tell Us About PTC Therapeutics (PTCT) Q4 Earnings (Zacks)
05:20PM	PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:33PM	PTC Therapeutics Inc (PTCT) Reports Robust Revenue Growth and Advances in Pipeline (GuruFocus.com)
04:30PM	PTC Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:05PM	PTC Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Feb-27-24 05:20PM	PTC Therapeutics to Participate at Upcoming Investor Conferences (PR Newswire)
Feb-26-24 09:16AM	Wall Street's Insights Into Key Metrics Ahead of PTC Therapeutics (PTCT) Q4 Earnings (Zacks)
Feb-22-24 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Feb-15-24 08:00AM	PTC Therapeutics to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results (PR Newswire)
Feb-13-24 10:00AM	PTC Therapeutics (PTCT) to Report Q4 Results: Wall Street Expects Earnings Growth (Zacks) -6.83%
Feb-11-24 01:45AM	1 of Sarepta Therapeutics' Competitors Just Got Hammered. Will It Help the Stock? (Motley Fool)
Jan-26-24 04:06PM	PTC Therapeutics Recovers From An Ugly Fall After European Officials Reject DMD Drug (Investor's Business Daily)
11:45AM	PTC Therapeutics Recovers, Mostly, After European Officials Reject DMD Drug (Investor's Business Daily)
10:18AM	PTC Therapeutics Flashes A Bearish Sign After European Officials Reject DMD Drug (Investor's Business Daily)
Jan-25-24 04:51PM	UPDATE 1-Europe to withdraw PTC Therapeutics' rare muscle disorder drug (Reuters)
04:20PM	PTC Therapeutics' muscle disorder drug fails to secure EU regulator backing (Reuters)
04:05PM	CHMP Issues Negative Opinion for Renewal of Conditional Marketing Authorization for Translarna (ataluren) Following Re-examination Procedure (PR Newswire)
Jan-24-24 07:02PM	PTC Therapeutics Inc Director Allan Jacobson Sells 10,000 Shares (GuruFocus.com)
Jan-12-24 01:02AM	PTC Therapeutics Inc Chief Business Officer Eric Pauwels Sells 3,634 Shares (GuruFocus.com) -5.01%
Jan-08-24 09:26AM	PTC Therapeutics Provides an Update on Commercial Progress and R&D Pipeline at 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire) +7.49%
Jan-03-24 08:00AM	PTC Therapeutics to Participate at 42nd Annual J.P. Morgan Healthcare Conference (PR Newswire)
Dec-20-23 09:41AM	Analysts on Wall Street Lower Ratings for These 5 Stocks (Insider Monkey)
Dec-15-23 05:01PM	Insider Buying: CFO Pierre Gravier Acquires 7,700 Shares of PTC Therapeutics Inc (PTCT) (GuruFocus.com)
Dec-14-23 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire)
Dec-05-23 04:15PM	PTC Therapeutics Provides Updates on Translarna Regulatory Activities (PR Newswire)
Nov-14-23 03:58PM	FMR LLC Trims Stake in PTC Therapeutics Inc (GuruFocus.com) +9.71%
Nov-03-23 04:30PM	PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (PR Newswire) +8.08%
Oct-30-23 09:03AM	PTC Therapeutics, Inc. (NASDAQ:PTCT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Oct-27-23 11:22AM	Q3 2023 PTC Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -22.71%
10:01AM	Roblox upgraded, Bristol Myers downgraded: Wall Street's top analyst calls (The Fly)
08:33AM	Why Is PTC Therapeutics (PTCT) Stock Down 23% Today? (InvestorPlace)
07:15AM	The Zacks Analyst Blog Highlights Bristol Myers, PTC Therapeutics, Beam Therapeutics and BioMarin Pharmaceutical (Zacks)
02:38AM	Southwest Airlines slashed at TD Cowen following Q3 miss: 4 big analyst cuts (Investing.com)
Oct-26-23 07:30PM	PTC Therapeutics (PTCT) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
06:10PM	PTC Therapeutics Inc (PTCT) Reports Q3 2023 Earnings: Revenue of $197 Million (GuruFocus.com)
05:30PM	PTC Therapeutics (PTCT) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
04:25PM	PTC Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	PTC Therapeutics Provides Corporate Update and Reports Third Quarter Financial Results (PR Newswire)
Oct-24-23 10:00AM	Neurocrine Biosciences (NBIX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
Oct-19-23 07:02PM	Why PTC Therapeutics Soared 15% Higher Today (Motley Fool) +14.98%
10:01AM	PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
08:00AM	PTC Therapeutics Announces Evrysdi Royalty Agreement with Royalty Pharma for Up To $1.5 Billion (PR Newswire)
Oct-16-23 04:30PM	PTC Therapeutics to Host Conference Call to DiscussThird Quarter 2023 Financial Results (PR Newswire)

PTC Therapeutics, Inc. is a biopharmaceutical company, which focuses on the discovery, development, and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The company was founded by Allan Steven Jacobson and Stuart Walter Peltz on March 31, 1998 and is headquartered in Warren, NJ.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gravier Pierre	CHIEF FINANCIAL OFFICER	Jul 16 '24	Sale	34.02	2,269	77,200	53,531	Jul 18 05:20 PM
ZELDIS JEROME B	Director	May 22 '24	Option Exercise	26.42	20,000	528,400	34,500	May 24 05:20 PM
ZELDIS JEROME B	Director	May 22 '24	Sale	38.24	20,000	764,800	14,500	May 24 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	May 07 '24	Sale	32.82	175	5,744	59,813	May 08 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Apr 19 '24	Sale	24.89	3,361	83,669	225,807	Apr 22 05:20 PM
Pauwels Eric	CHIEF EXECUTIVE OFFICER	Apr 17 '24	Sale	25.14	787	19,781	67,694	Apr 19 05:20 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Apr 17 '24	Sale	25.14	1,307	32,851	229,168	Apr 19 05:20 PM
Golden Lee Scott	EVP & CHIEF MEDICAL OFFICER	Apr 02 '24	Sale	28.37	526	14,923	59,988	Apr 04 05:16 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 30 '24	Sale	27.25	618	16,841	61,202	Feb 01 04:18 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 30 '24	Sale	27.25	28	763	3,706	Feb 01 04:18 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 30 '24	Sale	27.25	794	21,637	71,189	Feb 01 04:17 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Jan 30 '24	Sale	27.25	366	9,974	44,181	Feb 01 04:16 PM
Utter Christine Marie	SVP, CHIEF ACCOUNTING OFFICER	Jan 30 '24	Sale	27.25	318	8,666	35,528	Feb 01 04:15 PM
Jacobson Allan Steven	Director	Jan 22 '24	Option Exercise	27.05	10,000	270,500	22,348	Jan 24 04:30 PM
Jacobson Allan Steven	Director	Jan 22 '24	Sale	27.38	10,000	273,804	12,348	Jan 24 04:30 PM
Utter Christine Marie	SVP, FINANCE & CAO	Jan 09 '24	Sale	29.01	1,653	47,961	35,846	Jan 10 04:11 PM
Utter Christine Marie	SVP, FINANCE & CAO	Jan 08 '24	Sale	28.64	1,188	34,025	37,499	Jan 10 04:11 PM
SCHMERTZLER MICHAEL	Director	Jan 08 '24	Sale	27.81	1,500	41,715	115,266	Jan 10 04:10 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Jan 09 '24	Sale	29.01	2,065	59,916	44,547	Jan 10 04:09 PM
Pauwels Eric	CHIEF BUSINESS OFFICER	Jan 08 '24	Sale	28.64	1,569	44,937	46,612	Jan 10 04:09 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Jan 09 '24	Sale	29.01	5,443	157,928	160,475	Jan 10 04:08 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Jan 08 '24	Sale	28.64	2,237	64,068	165,918	Jan 10 04:08 PM
Golden Lee Scott	CHIEF MEDICAL OFFICER	Jan 09 '24	Sale	29.01	1,225	35,543	37,914	Jan 10 04:06 PM
Golden Lee Scott	CHIEF MEDICAL OFFICER	Jan 08 '24	Sale	28.64	775	22,196	39,139	Jan 10 04:06 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 09 '24	Sale	29.01	1,938	56,231	71,983	Jan 10 04:04 PM
Boulding Mark Elliott	EXEC. VP AND CLO	Jan 08 '24	Sale	28.64	1,457	41,729	73,921	Jan 10 04:04 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 09 '24	Sale	29.01	1,521	44,132	61,820	Jan 10 04:03 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 08 '24	Sale	28.64	1,236	35,399	63,341	Jan 10 04:03 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 09 '24	Sale	29.01	100	2,901	3,734	Jan 10 04:03 PM
Almstead Neil Gregory	CHIEF TECHNICAL OPS OFFICER	Jan 08 '24	Sale	28.64	53	1,518	3,834	Jan 10 04:03 PM
Klein Matthew B.	CHIEF EXECUTIVE OFFICER	Jan 05 '24	Sale	27.15	10,107	274,393	168,155	Jan 09 04:29 PM
Gravier Pierre	CHIEF FINANCIAL OFFICER	Dec 12 '23	Buy	25.81	7,700	198,736	33,700	Dec 14 04:38 PM

RCKT

Rocket Pharmaceuticals Inc

PTCT

PTC Therapeutics Inc

Upgrade your FINVIZ experience